Analyst Reco. Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
49.86 ^USD	+4.03%		+4.90%	-16.71%

04-26	Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment	MT
04-26	Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating	04-17	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	04-09	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	03-21	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	03-20	MT
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating	03-06	MT
UBS Raises Apellis Pharmaceuticals Price Target to $89 From $87, Maintains Buy Rating	03-04	MT
Wedbush Raises Apellis Pharmaceuticals' PT to $67 From $60, Keeps Neutral Rating; Says Awaiting Further Clarity on Potential EU Regulatory Path for Syfovre	02-28	MT
Mizuho Raises PT on Apellis Pharmaceuticals to $60 From $49 Ahead of Q4 2023 Earnings Announcement, Keeps Neutral Rating	02-15	MT
UBS Adjusts Apellis Pharmaceuticals Price Target to $87 From $70, Maintains Buy Rating	02-13	MT
North American Morning Briefing : Rate Doubts Keep -2-	02-06	DJ
Jefferies Upgrades Apellis Pharmaceuticals to Buy From Hold, Adjusts Price Target to $80 From $68	02-05	MT
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $79 From $75, Maintains Outperform Rating	01-30	MT
Needham Adjusts Price Target on Apellis Pharmaceuticals to $75 From $70, Maintains Buy Rating	01-24	MT
Wells Fargo Raises Apellis Pharmaceuticals' Price Target to $62 From $54, Maintains Equalweight Rating	01-17	MT
Baird Adjusts Apellis Pharmaceuticals' Price Target to $81 From $71, Maintains Outperform Rating	01-17	MT
Raymond James Adjusts Apellis Pharmaceuticals' Price Target to $106 From $67, Maintains Strong Buy Rating	01-11	MT
Goldman Sachs Adjusts Price Target on Apellis Pharmaceuticals to $90 From $65, Maintains Buy Rating	01-09	MT
Citigroup Adjusts Apellis Pharmaceuticals' Price Target to $67 From $70, Maintains Buy Rating	12-15	MT
Oppenheimer Cuts Apellis Pharmaceuticals Price Target to $75 From $88, Maintains Outperform Rating	12-15	MT
Raymond James Adjusts Price Target on Apellis Pharmaceuticals to $67 From $93, Keeps Strong Buy Rating	12-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Analyst Reco.

Filters